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Abstract 
 
Background: Prostate cancer (PCa) is the most common causing cancer-related in death in men and lack of reliable 
diagnostic tool. MicroRNAs are small molecules single-stranded RNA that affecting protein expression at the level 
of translation and dysregulation can dramatically affect cell metabolism. However, the using of circulating miRNAs 
as diagnostic biomarkers for diagnosis of PCa is still unknown. 
Methods: Ten patients with prostatic hyperplasia with high-level of PSA and 10 healthy controls were conducted in 
this study. The reverse transcription of miRNA based on quantitative polymerase chain reaction (qPCR) were used 
for evaluating the dysregulation of miRNA 30b-3p and using of ELISA to evaluate the level of prostate-specific 
antigen (PSA) and testosterone hormone. 
Results: Circulating miRNA 30b-3p level was increased in patients with prostatic hyperplasia with higher level of 
PSA as compared with healthy controls. Also, the testosterone hormone was increased in those patients as compared 
with normal level of testosterone in healthy individuals. 
Conclusion: The serum miRNA 30b-3p level increased in patients with hyperplasia in prostate and may be one of 
potential biomarker for diagnosis of PCa. 
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1. Introduction 
 
Prostate cancer (PCa) is the most commonly 
diagnosed new solid cancer and the second most 
common causing cancer-related death in men in the 
United States (1). The prostate-specific antigen (PSA) 
concentration in the blood is a test approved by the US 
food and drug administration as an aid to the early 
detection of PCa (2). Screening with PSA has been 
widely used to detect PCa for decades in the United 
States and many industrialized nations, but it continues 
to be controversial. Until a few years ago, the American 
cancer society and the American Urological 
Association recommended PCa screening for men at 
average risk who are 50 years or older and have an 
expectancy of life at least 10 years, after the patient and 
physician discuss the risk and benefits of screening and 
intervention (3). 
Prostate-specific antigen (PSA) is a member of the 
human kallikrein of serine proteases family with the 
PSA gene (KLK3) encoding for the protein hk3 (4). 
All kallikreins are serine proteases that are 
produced as pre and proenzymes and all have conserved 
positioning of the aspartate/histidine/serine catalytic 
triad. Of the kallikreins that have been characterized, 
most have trypsin-like proteolytic activity. PSA 
however, differs from the rest of family in that it has 
achymotrypsin-like substrate specificity, cleaving after 
hydrophobic residues. The major physiological 
proteolytic of substrates for PSA appears to be the gel 
forming proteins in freshly ejaculated semen, 
semenogelin I (Sg I) and semenogelin II (Sg II) are 
synthesized and secreted by seminal vesicles (5). The 
identification of PSA processing protease may also 
yield insights into why varying ratios of different 
molecular forms of PSA are present in human serum in 
patients with normal prostates compared to those with 
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benign prostatic hyperplasia (BPH) or prostate 
cancer(6). 
PSA presenting in the serum in a number of 
different forms, all forms are enzymatically inactive. 
These can be classified into two general categories: 
complex PSA (i.e. initially enzymatically active but 
now inactive due to binding to serum protease 
inhibitors) and free PSA (i.e. unbound, never active 
PSA) (7). 
Approximately 65-95% of PSA in the serum is 
PSA bound to ACT (PSA-ACT) and this is the 
predominant form of PSA in the serum in men with 
normal prostate, BPH or prostate cancer. The remaining 
PSA consists of free PSA forms (5-35%) that are 
enzymatically inactive (either as incorrectly processed 
pro-PSA or PSA protein that has been proteolytically 
cleaved) and, therefore unable to complex with serum 
protease inhibitors. Antibodies are available that bind 
selectively to free, un-complex PSA and these form the 
basis of clinical testing measuring the ration of free 
PSA to the total PSA. This ratio decreases in patients 
with prostate cancer (i.e. decreased free and/ or higher 
total PSA consistent with higher amounts of active PSA 
entering blood serum) and increasingly used to 
differentiate BPH from prostate cancer in men with 
serum PSA (8). 
MicroRNAs are small molecules single-stranded of 
RNA that affecting protein expression at the level of 
translation, and dysregulation can dramatically affect 
cell metabolism. Comparison of 736 microRNAs 
expression levels between the poorly metastatic SV40T 
immortalized prostate epithelial cell line P69 to its 
highly tumorigenic and metastatic subline M12 
identified 231 miRs that were overexpressed (9). 
MicroRNAs represent non-coding RNAs that are 
important for stem cell development in embryonic state 
and epithelial to mesenchymal transition (EMT). Tumor 
cells hijack EMT and stemness to grow and metastasize 
to distant organs including bone. Tumor 
microenvironment and tumor cells interaction with 
stromal fibroblasts at the primary and metastatic sites 
and this interaction could lead to tumor growth, EMT 
and bone metastasis (10). 
The role of RNAs in non-coding state in EMT and 
metastasis of cancer cells remains poorly understood. 
Recent studies highlight the directive functions of non-
coding RNAs including microRNAs (miRNAs) and 
long non-coding RNAs (IncRNAs) in modulating 
cancer cell growth, survival EMT and metastasis (11). 
In contrast to IncRNA, microRNAs are small (20-
23 nucleotides) non-coding ribonucleic acid (RNA) 
molecules which bind to complementary sites in the 
messenger RNAs (mRNAs) of their target genes, 
thereby inducing the post-transcriptional silencing of 
genes. It is predicted that miRNAs might regulate up to 
one-third of all genes (12). 
The presumed number of unidentified miRNAs is 
large. Currently about, 1881 miRNAs are identified in 
Homo sapiens (human) based on miR base. 
MicroRNAs are located throughout the genome 
including intergenic regions and in the introns of both 
protein-coding and non-coding genes (13,14). 
Testosterone is one of the principal androgen in 
circulation, while dihydrotestosterone (DHT) is the 
primary nuclear androgen and the most potent androgen 
in tissue. the adults males circulation contain, roughly 
44% of testosterone bounding with high affinity to sex 
hormone binding globulin (SHBG), 54% bounding with 
low affinity to albumin and only 1-2% of testosterone 
exists in a free (unbound) state. About 25% of DHT in 
the circulation is secreted by the testis while most 
(65%-75%) arises from conversion of testosterone in 
peripheral tissue (15). 
The prostate is a major site in men with no 
testicular DHT production from testosterone. In 
circulation free testosterone enters prostate cells by 
method of passive diffusion. In 1941 Charles Huggins 
shows that blocking the production of testosterone 
slows the growth of prostate cancer. Sixty-five years 
after Huggins findings', we are not much further ahead; 
we are still blocking testosterone to slow the growth of 
prostate cancer, especially in cases when cancer has 
spread. Additional evidence that testosterone is 
involved in causing prostate cancer comes from 
different sources. Rats were given high doses of 
testosterone develop prostate cancer (16). The men who 
are castrated prior to puberty do not produce 
testosterone do not develop prostate cancer. Men with 
cirrhosis of liver, a condition that increases their female 
sex hormone, which suppresses testosterone have lower 
incidence of prostate cancer (17). 
 
2. Material and Methods 
 
Ten patients who attended the urology department 
between January to March 2017 in teaching hospital of 
medical city in Baghdad and underwent PSA values. 
The patients aged between 48 to 65 years with prostate 
hyperplasia and PSA levels between 6-15ng/ml. Ten 
individuals enrolled in this study aged between 50 to 60 
years with normal values of PSA as control group. 
There are some exclusion criteria for the patients used: 
first, the age above 75 years excluded, urinary infection 
excluded, bladder stones and catheterization were 
excluded. 
 
2.1 Selection of miRNA 
 
 
 
hsa-miR-30b-3p MIMAT0004589
hmiR-30b-3p RT primer
hmiR-30b-3p-F
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2.2 RNA isolation 
 
Total RNA was isolated from patient's serum and 
control using Trizol Reagent (Life 
Technologies/Invitrogen) according to the instructions. 
Messenger RNA Specific RT-qPCR: cDNA 
synthesis was performed with Tetro Reverse 
Transcriptase kit (Bioline Ltd.) according to the 
manufacturer’s recommendation. Quantitative PCR was 
performed using real-time PCR (ABI PRISM 7900HT, 
Applied Biosystems). PRMT1 (Mm0048135_g1) 
TaqMan gene expression assay was used and quantified 
by the comparative DCT method and normalized to 
GAPDH (Mm99999915_g1) expression. 
 
2.3 Reverse transcription and real-time PCR 
 
A total of 4µL of purified RNA (from a total 
volume of 100µL eluate) was reverse-transcribed using 
the miRCURY LNA™ Universal RT microRNA PCR, 
Polyadenylation and cDNA synthesis kit (Exiqon). A 
total of 0.5µL of UniSp6 RNA was spike-in the RT mix 
for the quality control of cDNA synthesis. The total 
reaction volume was 10µL. Primers for mature 
sequences of selected miRNAs were purchased from 
Exiqon (microRNA LNA™ PCR primer set). No-
template controls were included. All PCR assays (total 
reaction volume: 20µL) were run on an iCycler iQ™ 
Real-Time PCR Detection System (Bio-Rad 
Laboratories, Hercules, CA, USA). SYBR Green 
master mix was used (miRCURY LNA™ Universal RT 
microRNA PCR SYBR® Green Master Mix; Exiqon). 
PCR amplification efficiencies were calculated for each 
individual miRNA using the following equation:  
 
E = (10−1/slope−1) ×100                         (1) 
 
The efficiency threshold was calculated at ±10% 
across a 10-fold dilution series across five points. 
Candidate housekeeping genes were selected on the 
basis of literature data and manufacturer’s 
recommendations. After stability assessment assays, 
data were normalized against the mean between miR-
191-5p and miR-425-5p Ct values as follows:  
 
ΔCt = −(Cttarget − CtmiR-191-5p+miR-425-5p)           (2) 
 
Values are reported as the mean ± SD. 
 
3. Results 
 
Table (1) show the level of expression of 
microRNA in patients with hyperplasia in prostate with 
high-level pf PSA and control group which show 
elevated level of miRNA in patients compared with 
healthy control. 
 
Table 1. The level expression of miRNA 30b-3p in patients and control group. 
 
Groups Samples RNU miR30-b DCt DDCt miR30-b miR30-b 
Patient 
1 32.2 39.1 6.9 1.61 0.33 
1.51 
2 31.5 37.7 6.2 0.91 0.53 
3 31.5 41.6 10.1 4.81 0.04 
4 32.5 37.7 5.2 -0.09 1.06 
5 31.7 34.5 2.8 -2.49 5.62 
6 32 37.6 5.6 0.31 0.81 
7 31.4 37.7 6.3 1.01 0.50 
8 31.2 37.9 6.7 1.41 0.38 
9 31.6 34.7 3.1 -2.19 4.56 
10 31.3 36.2 4.9 -0.39 1.31 
Control 
11 31.6 35.5 3.9 -1.39 2.62 
1.43 
12 31.1 35.3 4.2 -1.09 2.13 
13 30.1 37 6.9 1.61 0.33 
14 30.5 34.4 3.9 -1.39 2.62 
15 31.1 37.1 6 0.71 0.61 
16 30.5 35.9 5.4 0.11 0.93 
17 31.6 35.1 3.5 -1.79 3.46 
18 30 35.5 5.5 0.21 0.86 
19 30.3 37.1 6.8 1.51 0.35 
20 30.3 37.1 6.8 1.51 0.35 
CUGGGAGGUGGAUGUUUACUUC
GTTGGCTCTGGTGCAGGGTCCGAGGTATTCGCACCAGAGCCAAC GAAGTA
GTTCTGGGAGGTGGATGTT 
hsa-miR-30d-5p MIMAT0000245
hmiR-30d-5p RT primer
hmiR-30d-5p-F
UGUAAACAUCCCCGACUGGAAG
GTTGGCTCTGGTGCAGGGTCCGAGGTATTCGCACCAGAGCCAAC CTTCCA
GTGTGTAAACATCCCCGAC
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Table 2. Compare between patients and control in parameters. 
 
The Group No. Mean ± SE 
miR30-b () PSA () Testosterone () 
Patients 10 1.514 ± 0.61 7.860 ± 0.28 8.520 ± 0.49 
Control 10 0.870 ± 0.21 1.540 ± 0.28 3.800 ± 0.50 
T-test --- 1.362 NS 3.202 ** 1.468 ** 
P-value --- 0.334 0.0006 0.0001 
** (P<0.01), NS: Non-significant. 
 
Table 3. Correlation coefficient between parameters. 
 
Parameters  Correlation coefficient-r Level of sig. 
miR30-b& PSA 0.38 * 
miR30-b& Testosterone 0.36 * 
PSA & Testosterone 0.70 ** 
* (P<0.05), ** (P<0.01). 
 
Table (2) show the comparison between patients 
and the control group in miRNA, PSA, and testosterone 
hormone which shows significant difference in PSA, 
and testosterone (p<0.01) in patients compared with 
healthy control. 
Table (3) show the correlation between the 
parameters which show significant difference between 
miRNA and PSA (p<0.05), also a significant difference 
with testosterone (p<0.05) and a significant difference 
of PSA with testosterone (p<0.01). 
 
4. Discussion 
 
The dysregulation of miRNAs has been widely 
identified in different kinds of human cancers and 
demonstrating their important roles during cancer 
development and progression. The mechanisms that 
possible underlying the importance of miRNAs is 
uncovering in the pathogenesis of human cancers may 
lead to the development of miRNA based therapeutic 
strategies or diagnostic/prognostic biomarkers (18). 
In the fact that current cancer detection test 
considering have their own limitations, the using of 
miRNAs as promising biomarkers for diagnosis and 
prognosis of cancer has aroused intense research 
interest. Additionally to the distinctive pattern of 
miRNA expression also serves as markers of important 
histopathologic features such as tumor stage, 
proliferative capacity and vascular invasion (19). The 
Real-time PCR which is used to validate the expression 
of miRNAs discovered during high throughput arrays 
and studies the expression of individual miRNAs (20). 
Recent evidence suggests that miRNA profiles 
from tissue sources as well as from circulating body 
fluids could be good tools for prognostic and diagnostic 
purposes. MiRNAs profiles not only can distinguish 
between tumors of different developmental origin but 
also possess prerequisites to be considered useful 
noninvasive detection biomarkers. First, exceptionally, 
they are stable in different clinical samples such as 
formalin-fixed, paraffin-embedded tissue, blood, serum 
and urine. Second, they can be measured quantitatively 
reliable in small amounts of samples by real-time 
quantitative reverse transcription polymerase chain 
reaction (RT-PCR). Third, they are resistant to 
endogenous ribonuclease activity as well as variation in 
temperature and PH. In addition, among different 
species making the use of animals for preclinical 
studies feasible, they are highly conserved (21). 
miRNA 30b-3p regulate androgen receptor in 
prostate biology and in the development of prostate 
cancer (PCa) (22). 
Different studies have examined the expression of 
miRNA in serum or plasma in purpose to develop a 
blood-based diagnostic procedure for development and 
diagnosis of PCa. 
In the present study, the serum level expression of 
miRNA 30b-3p can distinguish from healthy controls 
which show increased expression of miRNA30b-3p in 
patients with high-level of PSA. 
Mitchel et al., diagnose in his study that serum 
level of miRNA-141 can distinguish PCa patients from 
healthy control which support the potential role of this 
miRNA as a diagnostic marker of PCa (23). 
Mahn et al., study the oncogenic miRNAs in 
circulation and found miRNA-269 has sensitivity of 
89% and specificity of 56% (24). 
Chen et al., examined a panel of 5 serum miRNAs 
(let-7c, let-7e, miR-30c-622 and 1285) significantly 
different in PCa patients when compared with healthy 
control group. All miRNAs could distinguish PCa from 
healthy controls individually (25). 
Selth et al., (26) studied on mouse model having 
PCa as a tool to discover serum miRNAs that could be 
used in clinical setting. miRNA (miR-141, -298, -346, 
and 375), these miRNAs among 45 miRNAs elevated 
significantly in mouse with metastatic PCa compared to 
those in healthy controls. 
In a study of 51 PCa patients in Turkey compared 
with 20 healthy controls. Investigated the miRNA-21,   
-41 and -221 levels in plasma of patients compared to 
healthy control, they found that miR-21 and miR-221 
levels were higher significantly in prostate patients than 
controls (27).  
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In our study which is the first study in Iraq that 
distinguish the expression the level of miRNA 30b-3p 
in patients with hyperplasia in prostate with high-level 
of PSA, there is evidence that alteration in miRNA 
function plays a role in prostatic carcinogenesis. The 
miRNAs dysregulation effect on a number of critical 
cellular processes involved in this process, this process 
including but not limited to: the cell cycle stimulation, 
apoptosis avoidance and modulation of androgen 
receptor-mediated signaling (18). 
Serum androgens may not accurately reflect the 
true androgenic environment within the prostate. 
Testosterone is the major circulating androgen. 
In a different analysis of 18 prospective studies, 
Roddam and collaborative group reported on the 
endogenous hormone and prostate cancer no association 
between blood levels of total testosterone and prostate 
cancer risk cancer risk based on data from 3,886 men 
with prostate cancer and 6,438 controls. It is largest 
serum based study with the most elegant and 
comprehensive analysis to date to test a central 
hypothesis in prostate cancer etiology. It is not 
surprising that the pooled analysis did not find a 
positive link between circulating levels of total 
testosterone and prostate cancer risk since, individually, 
few of the 18 studies included in the pooled analysis 
reported a significant positive association (28). 
From the study of the European prospective 
investigation into cancer and nutrition (EPIC) (with 643 
case-control pairs) identified a significant inverse 
association of androstenedione concentration and risk 
for advanced prostate cancer, and weak positive 
association between free testosterone concentration and 
risk for total prostate cancer among men and risk for 
high grade disease (29). 
Several different reasons which contribute to the 
mixed results from epidemiologic studies. First, the 
androgenic serum levels are indirect indicators of 
intraprostatic androgen levels and may not an accurate 
reflection of androgen action within the prostate. In 
addition, relatively large assay variation, intrapersonal 
variation, study population differences, and 
heterogeneity of prostate cancer in these studies to 
replicate results. Furthermore, genetic susceptibility in 
the androgen metabolic and signaling pathways may 
contribute to the effects that androgens have on prostate 
cancer. Another study have measured testosterone and 
DHT in individuals which show definitely that men 
with higher serum levels of testosterone have higher 
risk of prostate cancer. 
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